
## Tomoyuki Nagata

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6573983/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association between DNA Methylation of the BDNF Promoter Region and Clinical Presentation in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2015, 5, 64-73.	1.3	65
2	Increase in the IgG avidity index due to herpes simplex virus type 1 reactivation and its relationship with cognitive function in amnestic mild cognitive impairment and Alzheimer's disease. Biochemical and Biophysical Research Communications, 2013, 430, 907-911.	2.1	62
3	Plasma BDNF levels are correlated with aggressiveness in patients with amnestic mild cognitive impairment or Alzheimer disease. Journal of Neural Transmission, 2014, 121, 433-441.	2.8	36
4	Association between executive dysfunction and hippocampal volume in Alzheimer's disease. International Psychogeriatrics, 2011, 23, 764-771.	1.0	33
5	Association between BDNF Polymorphism (Val66Met) and Executive Function in Patients with Amnestic Mild Cognitive Impairment or Mild Alzheimer Disease. Dementia and Geriatric Cognitive Disorders, 2012, 33, 266-272.	1.5	33
6	Development of Biomarkers Based on DNA Methylation in the NCAPH2/LMF2 Promoter Region for Diagnosis of Alzheimer's Disease and Amnesic Mild Cognitive Impairment. PLoS ONE, 2016, 11, e0146449.	2.5	29
7	Psychosocial or clinicoâ€demographic factors related to neuropsychiatric symptoms in patients with Alzheimer's disease needing interventional treatment: analysis of the CATIEâ€AD study. International Journal of Geriatric Psychiatry, 2017, 32, 1264-1271.	2.7	27
8	Relationship of frontal lobe dysfunction and aberrant motor behaviors in patients with Alzheimer's disease. International Psychogeriatrics, 2010, 22, 463-469.	1.0	26
9	Usefulness of DNA Methylation Levels in COASY and SPINT1 Gene Promoter Regions as Biomarkers in Diagnosis of Alzheimer's Disease and Amnestic Mild Cognitive Impairment. PLoS ONE, 2016, 11, e0168816.	2.5	26
10	Correlation between a reduction in Frontal Assessment Battery scores and delusional thoughts in patients with Alzheimer's disease. Psychiatry and Clinical Neurosciences, 2009, 63, 449-454.	1.8	25
11	A case in which mirtazapine reduced auditory hallucinations in a patient with Parkinson disease. International Psychogeriatrics, 2013, 25, 1199-1201.	1.0	21
12	Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study. Journal of Alzheimer's Disease, 2016, 50, 839-845.	2.6	19
13	Differentiation between amnesticâ€mild cognitive impairment and earlyâ€stage Alzheimer's disease using the Frontal Assessment Battery test. Psychogeriatrics, 2011, 11, 235-241.	1.2	17
14	Increased blood COASY DNA methylation levels a potential biomarker for early pathology of Alzheimer's disease. Scientific Reports, 2020, 10, 12217.	3.3	17
15	Association between brainâ€derived neurotrophic factor ( <i>BDNF</i> ) gene polymorphisms and executive function in Japanese patients with Alzheimer's disease. Psychogeriatrics, 2011, 11, 141-149.	1.2	15
16	Anosognosia in patients with Alzheimer's disease: current perspectives. Psychogeriatrics, 2020, 20, 345-352.	1.2	14
17	Association between Neuropsychiatric Improvement and Neurocognitive Change in Alzheimer's Disease: Analysis of the CATIE-AD Study. Journal of Alzheimer's Disease, 2018, 66, 139-148.	2.6	13
18	Effectiveness of carbamazepine for benzodiazepineâ€resistant impulsive aggression in a patient with frontal infarctions. Psychiatry and Clinical Neurosciences, 2007, 61, 695-697.	1.8	10

Τομογικι Νασατά

#	Article	IF	CITATIONS
19	Association between Nerve Growth Factor Gene Polymorphism and Executive Dysfunction in Japanese Patients with Early-Stage Alzheimer's Disease and Amnestic Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2011, 32, 379-386.	1.5	10
20	Anosognosia in mild <scp>A</scp> lzheimer's disease is correlated with not only neural dysfunction but also compensation. Psychogeriatrics, 2018, 18, 81-88.	1.2	10
21	Cognitive Dysfunction in Patients With Late-Life Somatic Symptom Disorder: A Comparison According to Disease Severity. Psychosomatics, 2015, 56, 486-494.	2.5	9
22	Sex differences in the severity of neuropsychiatric symptoms and their relationship with clinico-demographic and psychosocial factors in patients with amnestic mild cognitive impairment and mild Alzheimer's disease. Aging and Mental Health, 2020, 24, 431-438.	2.8	8
23	Effects of neuropsychiatric symptoms of dementia on reductions in activities of daily living in patients with Alzheimer's disease. Geriatrics and Gerontology International, 2020, 20, 584-588.	1.5	8
24	Genetic Association between Neurotrophin-3 Polymorphisms and Alzheimer's Disease in Japanese Patients. Dementia and Geriatric Cognitive Disorders Extra, 2013, 3, 272-280.	1.3	7
25	Baseline Predictors of Antipsychotic Treatment Continuation and Response at Week 8 in Patients with Alzheimer's Disease with Psychosis or Aggressive Symptoms: An Analysis of the CATIE-AD Study. Journal of Alzheimer's Disease, 2017, 60, 263-272.	2.6	7
26	Pharmacological management of behavioral disturbances in patients with Alzheimer's disease. Expert Opinion on Pharmacotherapy, 2020, 21, 1093-1102.	1.8	7
27	Early Improvements of Individual Symptoms With Antipsychotics Predict Subsequent Treatment Response of Neuropsychiatric Symptoms in Alzheimer's Disease. Journal of Clinical Psychiatry, 2020, 81,	2.2	6
28	Suppressors of Cytokine Signaling Are Decreased in Major Depressive Disorder Patients. Journal of Personalized Medicine, 2022, 12, 1040.	2.5	6
29	Genetic association between <i>RAGE</i> polymorphisms and Alzheimer's disease and Lewy body dementias in a Japanese cohort: a case–control study. International Journal of Geriatric Psychiatry, 2017, 32, 1241-1246.	2.7	5
30	A case of V180I genetic mutation Creutzfeldt Jakob disease (CJD) with delusional misidentification as an initial symptom. Prion, 2022, 16, 7-13.	1.8	5
31	Anorexia nervosa with chronic episodes for more than 30 years in a patient with a comorbid schizotypal personality disorder. Psychiatry and Clinical Neurosciences, 2007, 61, 434-436.	1.8	4
32	Association between the catecholâ€Oâ€methyltransferase polymorphism Val158Met and Alzheimer's disease in a Japanese population. International Journal of Geriatric Psychiatry, 2015, 30, 927-933.	2.7	4
33	Correlation between cognition and symptomatic severity in patients with late-life somatoform disorders. Aging and Mental Health, 2015, 19, 169-174.	2.8	4
34	Executive Dysfunction Correlated With 2-Year Treatment Response in Patients With Late-Life Undifferentiated Somatoform Disorders. Psychosomatics, 2016, 57, 378-389.	2.5	3
35	Blood DNA Methylation Levels in the WNT5A Gene Promoter Region: A Potential Biomarker for Agitation in Subjects with Dementia. Journal of Alzheimer's Disease, 2021, 81, 1601-1611.	2.6	3
36	Education level is associated with neuropsychiatric symptoms in patients with amnesticâ€mild cognitive impairment. Psychogeriatrics, 2022, 22, 343-352.	1.2	3

#	Article	IF	CITATIONS
37	Age-Related Association between Apolipoprotein E e4 and Cognitive Function in Japanese Patients with Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2013, 3, 66-73.	1.3	2
38	Genetic Association between Presenilin 2 Polymorphisms and Alzheimer's Disease and Dementia of Lewy Body Type in a Japanese Population. Dementia and Geriatric Cognitive Disorders Extra, 2016, 6, 90-97.	1.3	2
39	The timeâ€dependent trajectory of neuropsychiatric symptoms in patients with Alzheimer's disease. Psychogeriatrics, 2020, 20, 542-543.	1.2	1